Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging

Summary

1. It is a multicenter, open-label, sing arm study to evaluate the effects of treatment of Rosuvastatin 10-20mg in volume and morphology of atherosclerotic plague by reducing LDL-C level to or less than 70mg/dl. 2. Ischemic stroke patients will be enrolled within 1 month after stroke onset. 3. Patients will be visited at 0m, 1m, 3m, 6m, 9m, 12m, 18m and 24m.

Timeline

Start

2014-02-24

Primary completion

2018-11-06

Completion

2018-11-06

Drugs

Indications